FILTER

Refine your search with the following facets to narrow down your results.

37 Current news of Swedish Orphan Biovitrum

CEO Martin Nicklasson leaves Swedish Orphan Biovitrum

26-Nov-2010 - Swedish Orphan Biovitrum announced that CEO Martin Nicklasson will leave the company. The search for a new CEO will be initiated immediately. Kennet Rooth, currently head of marketing and sales, has agreed to assume the position as interim CEO for SOBI. Based upon the growth aspirations, the ...

Biovitrum

Swedish Orphan Biovitrum's co-promotion rights for Mimpara sold back to Amgen

09-Nov-2010 - Swedish Orphan Biovitrum announced a mutual agreement with Amgen whereby Swedish Orphan Biovitrum will sell back its co-promotion rights in the Nordic countries for Mimpara® (cinacalcet) to Amgen for strategic business reasons. Swedish Orphan Biovitrum will receive an undisclosed payment from ...

Amgen

Swedish Orphan Biovitrum appoints Anders Edvell as new Head of Sales and Marketing

05-Nov-2010 - Swedish Orphan Biovitrum announced that Anders Edvell has been appointed new VP of Marketing & Sales in Sobi. He will be the successor of Kennet Rooth, as he leaves his position January 10, 2011 for personal reasons. Anders Edvell is an MD and PhD in medicine, and has an MBA degree from the ...

business development medicine Sweden

Pharming's Ruconest(TM) for HAE granted European Marketing Authorization

01-Nov-2010 - Pharming Group NV and Swedish Orphan Biovitrum announced that the European Commission has granted Pharming Marketing Authorization for its lead product Ruconest(TM) for the treatment of acute attacks of Hereditary Angioedema (HAE). Pharming will now receive a €5 million milestone payment from ...

allergies Denmark Finland +10

Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP

08-Oct-2010 - Symphogen and Swedish Orphan Biovitrum announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia (ITP). ITP is an autoimmune bleeding disorder characterized by abnormally ...

clinical trials food immunoglobulins +2

Pharming and Swedish Orphan announce publication of randomized clinical trial results with recombinant human C1 inhibitor

07-Oct-2010 - Pharming Group NV and Swedish Orphan Biovitrum announced the publication of the integrated analysis of Pharming's randomized placebo-controlled clinical trials with recombinant human C1 esterase inhibitor (rhC1INH; conestat alfa; Ruconest(TM) in Europe; Rhucin® in other countries) for treatment ...

allergies clinical trials hereditary angioedema +4

Swedish Orphan Biovitrum's Hemophilia A Therapy Receives European Commission Orphan Drug Designation

24-Sep-2010 - Swedish Orphan Biovitrum announced that the European Commission has granted orphan drug designation to its long-lasting, fully-recombinant Factor FVIII Fc fusion protein (rFVIIIFc), which is partnered with Biogen Idec. It was recently announced that the companies plan to advance the rFVIIIFc ...

Biogen Idec clinical trials fusion proteins +4

Swedish Orphan Biovitrum's Kineret® has Received Orphan Drug Designation in the USA

30-Aug-2010 - Swedish Orphan Biovitrum announced that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to Kineret® for the treatment of cryopyrin-associated periodic syndromes (CAPS). CAPS is a rare autoinflammatory condition with very severe symptoms and is ...

Orphan Drug Designation orphan drugs

Biogen Idec and Swedish Orphan Biovitrum Decide to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial

13-Jul-2010 - Biogen Idec and Swedish Orphan Biovitrum announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data ...

antibodies Biogen Idec clinical trials +7

Swedish Orphan Biovitrum and Dongbao announce Commercial Alliance for the Chinese and European markets

08-Jul-2010 - Swedish Orphan Biovitrum and Dongbao announced their intent to form a strategic Commercial Alliance. In such an alliance, Swedish Orphan Biovitrum would be the marketing and sales partner of choice for Dongbao's pipeline of Biopharmaceuticals and other drugs in Europe and Dongbao would be the ...

biopharmaceuticals biotechnology China +1